…
Numinus Wellness Inc. provides psychedelic-assisted therapy training, lab testing, and psychotherapy services in Canada and the United States. The company operates through Clinical Research Operations and Practitioner Training segments. It also provides clinical research management services to academic institutions and biotechnology companies. In addition, the company engages in the provision of education and training for research and drug development organizations to support clinical trials and commercialization efforts. Numinus Wellness Inc. is headquartered in Vancouver, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 |
| Income before tax | -14.60M | -30.26M | -44.92M | -18.77M | -9.60M |
| Net income | -19.64M | -30.26M | -44.88M | -21.56M | -11.86M |
| Selling general administrative | 11.57M | 32.52M | 25.17M | 11.69M | 6.01M |
| Selling and marketing expenses | 0.77M | - | 2.19M | 2.22M | 0.91M |
| Gross profit | 1.17M | 8.37M | 1.78M | -0.08M | 0.09M |
| Reconciled depreciation | 0.56M | 2.83M | 1.51M | 0.72M | 0.61M |
| Ebit | -14.50M | - | -28.00M | -15.88M | -7.27M |
| Ebitda | -13.94M | - | -26.50M | -15.16M | -6.59M |
| Depreciation and amortization | 0.56M | - | 1.51M | 0.72M | 0.68M |
| Operating income | -11.71M | -26.96M | -28.00M | -15.88M | -7.27M |
| Other operating expenses | 15.88M | - | 34.94M | 17.35M | 8.15M |
| Interest expense | 0.10M | 0.76M | 0.56M | 0.11M | 0.14M |
| Tax provision | - | 0.00M | -0.03M | 0.00M | -0.01M |
| Interest income | 0.01M | 0.01M | 0.35M | 0.11M | 0.13M |
| Net interest income | -0.09M | -0.75M | -0.56M | -0.11M | -0.13M |
| Extraordinary items | -5.04M | - | - | - | - |
| Income tax expense | - | - | -0.03M | 2.78M | 2.26M |
| Total revenue | 4.17M | 23.18M | 6.49M | 1.51M | 0.88M |
| Total operating expenses | 12.87M | 50.14M | 30.23M | 15.76M | 7.36M |
| Cost of revenue | 3.00M | 14.81M | 4.72M | 1.60M | 0.79M |
| Total other income expense net | -2.89M | -2.55M | -16.91M | -2.90M | -2.33M |
| Net income from continuing ops | -14.60M | -30.26M | -44.88M | -18.77M | -9.60M |
| Net income applicable to common shares | -19.64M | - | -44.88M | -18.77M | -9.60M |
| Breakdown | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 |
| Total assets | 10.77M | 24.33M | 52.63M | 64.14M | 5.12M |
| Intangible assets | - | - | 0.34M | - | - |
| Other current assets | - | - | - | 0.00M | 0.09M |
| Total liab | 10.05M | 10.28M | 11.42M | 3.31M | 2.32M |
| Total stockholder equity | 0.73M | 14.05M | 41.21M | 60.83M | 2.80M |
| Other current liab | 5.79M | - | 0.20M | 0.15M | 0.17M |
| Common stock | - | - | 109.20M | 88.87M | 18.94M |
| Capital stock | 117.42M | 112.27M | 109.20M | 88.87M | 18.94M |
| Retained earnings | -136.51M | -116.87M | -86.61M | -41.73M | -22.95M |
| Other liab | - | - | 0.43M | 0.20M | - |
| Good will | - | 0.00M | 2.17M | - | - |
| Other assets | - | - | 0.24M | 0.02M | 0.01M |
| Cash | 1.96M | 8.58M | 33.04M | 59.29M | 1.63M |
| Total current liabilities | 8.61M | 4.64M | 4.58M | 1.91M | 2.01M |
| Current deferred revenue | - | - | 0.24M | 0.05M | - |
| Net debt | - | - | -25.19M | -57.69M | -1.21M |
| Short term debt | - | - | 1.44M | 0.40M | 0.11M |
| Short long term debt | 0.05M | 0.07M | 0.06M | - | - |
| Short long term debt total | - | - | 7.85M | 1.60M | 0.42M |
| Other stockholder equity | - | - | 1.09M | 0.50M | 6.82M |
| Property plant equipment | - | - | 11.38M | 3.15M | 2.44M |
| Total current assets | 9.80M | 12.05M | 36.12M | 60.97M | 2.67M |
| Long term investments | 0.00M | 2.08M | 2.37M | - | - |
| Net tangible assets | - | - | 38.70M | 60.83M | 2.80M |
| Short term investments | - | - | - | 0.00M | 0.01M |
| Net receivables | 0.76M | 1.77M | 1.60M | 0.52M | 0.54M |
| Long term debt | 0.15M | 0.16M | 0.21M | 0.00M | 0.04M |
| Inventory | - | - | 0.00M | 0.00M | 0.00M |
| Accounts payable | 1.29M | 2.89M | 2.71M | 1.30M | 1.73M |
| Accumulated other comprehensive income | - | - | 17.54M | 13.19M | 6.82M |
| Non currrent assets other | - | - | 0.24M | 0.02M | 0.01M |
| Non current assets total | 0.97M | 12.28M | 16.51M | 3.17M | 2.45M |
| Capital lease obligations | 1.83M | 6.96M | 7.57M | 1.60M | 0.38M |
| Long term debt total | - | - | 6.41M | 1.20M | 0.32M |
| Breakdown | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 | 2020-08-31 |
| Investments | 0.86M | -0.37M | 0.12M | 0.01M | 0.01M |
| Change to liabilities | - | - | -0.00M | -0.61M | 0.20M |
| Total cashflows from investing activities | 0.86M | - | 0.12M | -0.74M | -0.13M |
| Net borrowings | -0.56M | - | -0.68M | -0.33M | 0.16M |
| Total cash from financing activities | 4.54M | -1.46M | 0.01M | 73.98M | 7.02M |
| Change to operating activities | - | - | -0.36M | -1.23M | -0.54M |
| Net income | -19.64M | -30.26M | -44.88M | -18.77M | -9.60M |
| Change in cash | -6.62M | -24.46M | -26.25M | 57.67M | 1.54M |
| Begin period cash flow | 8.58M | 33.04M | 59.29M | 1.63M | 0.09M |
| End period cash flow | 1.96M | 8.58M | 33.04M | 59.29M | 1.63M |
| Total cash from operating activities | -12.43M | -22.76M | -26.23M | -15.58M | -5.36M |
| Issuance of capital stock | 5.31M | - | 0.00M | 57.15M | 6.13M |
| Depreciation | 0.56M | 2.83M | 1.51M | 0.72M | 0.61M |
| Other cashflows from investing activities | 0.03M | - | 1.37M | -0.10M | -0.16M |
| Change to inventory | - | - | 0.00M | -0.00M | 0.00M |
| Change to account receivables | 0.30M | -1.32M | 0.10M | -0.13M | -0.17M |
| Sale purchase of stock | 5.31M | - | 0.69M | 74.32M | 6.75M |
| Other cashflows from financing activities | -0.20M | - | 0.69M | 17.17M | 1.29M |
| Change to netincome | - | - | 17.41M | 4.45M | 4.14M |
| Capital expenditures | 0.03M | 0.38M | 1.25M | 0.64M | 0.04M |
| Change in working capital | 0.89M | -1.07M | -0.26M | -1.97M | -0.51M |
| Stock based compensation | 0.56M | 1.87M | 3.45M | 1.82M | 1.88M |
| Other non cash items | 5.19M | 0.12M | 13.99M | 2.63M | 2.26M |
| Free cash flow | -17.50M | -23.14M | -27.48M | -16.22M | -5.39M |
Sector: Healthcare Industry: Medical Care Facilities
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NUMI Numinus Wellness Inc |
- -% |
0.05 | - | - | 2.47 | 1.59 | 0.68 | -1.37 |
| EXE Extendicare Inc |
-0.53 1.87% |
27.76 | 25.21 | 23.92 | 1.59 | 7.26 | 1.62 | 14.43 |
| SIA Sienna Senior Living Inc |
0.19 0.94% |
20.42 | 45.94 | 38.17 | 2.23 | 3.17 | 3.57 | 21.90 |
| WELL WELL Health Technologies Corp |
0.06 1.33% |
4.20 | - | 13.87 | 0.80 | 1.23 | 1.09 | 9.83 |
| DR Medical Facilities Corporation |
-0.01 0.07% |
15.03 | 15.57 | 12.94 | 1.18 | 2.87 | 0.92 | 3.64 |
Numinus Wellness Inc. provides psychedelic-assisted therapy training, lab testing, and psychotherapy services in Canada and the United States. The company operates through Clinical Research Operations and Practitioner Training segments. It also provides clinical research management services to academic institutions and biotechnology companies. In addition, the company engages in the provision of education and training for research and drug development organizations to support clinical trials and commercialization efforts. Numinus Wellness Inc. is headquartered in Vancouver, Canada.
250 - 997 Seymour Street, Vancouver, BC, Canada, V6B 3M1
236 439 3098
| Name | Title | Year Born |
|---|---|---|
| Mr. Payton Nyquvest | Co-Founder, CEO & Chairman | NA |
| Mr. Michael Tan M.B.A. | Pres, COO & Director | NA |
| Mr. John Fong CPA, CGA | CFO & Corp. Sec. | NA |
| Dr. Evan Wood M.D., Ph.D. | Chief Medical Officer | NA |
| Dr. Paul Thielking M.D. | Chief Science Officer | NA |
| Jamie Kokoska | VP of Investor Relations | NA |
| Mr. Ian Noble | Chief Communications Officer | NA |
| Ms. Julie Saunders | Chief Marketing Officer | NA |
| Ms. Judy Varga M.Sc. | Head of Laboratory Operations | NA |
| Dr. Reid J. Robison M.D., MBA | Chief Clinical Officer | 1977 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.